Upgrade to SI Premium - Free Trial

Roche (RHHBY)

54.97 -0.25 (0.45%)

Chart
Today 6M 1Y 5Y

Latest Headlines

Roche Holding (ROG:SW) (RHHBY) PT Raised to CHF415 at BofA Securities September 4, 2026 6:06 AM - StreetInsider Roche wins FDA nod for HER2 companion diagnostics in GEA August 26, 2026 2:52 PM - StreetInsider Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA August 26, 2026 2:52 PM - PR NewsWire Flatiron Health Expands NSCLC Panoramic Dataset With Comprehensive Biomarker Data Model, Enabling Precision Medicine Research at Unprecedented Scale August 25, 2026 9:00 AM - BizWire Roche receives FDA clearance for Elecsys® pTau217, advancing Alzheimer's disease assessment across primary and specialty care August 24, 2026 7:00 AM - PR NewsWire Genentech Announces Manufacturing Expansion in Hillsboro, Oregon August 20, 2026 11:00 AM - BizWire Genentech Marks Topping out Milestone for New Holly Springs, North Carolina Manufacturing Facility August 18, 2026 3:40 PM - BizWire Morgan Stanley Upgrades Roche (RHHBY) to Overweight August 7, 2026 2:52 AM - StreetInsider Morgan Stanley Upgrades Roche Holding (ROG:SW) (RHHBY) to Overweight August 7, 2026 2:52 AM - StreetInsider Roche expands cyclospora testing portfolio to support U.S. public health response August 6, 2026 8:30 AM - PR NewsWire Buy this biotech stock into Q2 earnings: Analyst August 1, 2026 4:00 AM - StreetInsider Roche Holding (ROG:SW) (RHHBY) PT Raised to CHF434.50 at Bernstein SocGen Group July 27, 2026 9:30 AM - StreetInsider Roche wins FDA clearance for vaginitis PCR diagnostic test July 24, 2026 8:31 AM - StreetInsider Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis July 24, 2026 8:30 AM - PR NewsWire UBS Reiterates Buy Rating on Roche Holding (ROG:SW) (RHHBY) July 23, 2026 3:14 AM - StreetInsider Roche showcases intelligent lab solutions and high-precision instruments at ADLM 2026 to help laboratories address workforce and workflow challenges July 22, 2026 9:00 AM - PR NewsWire Roche names new diagnostics North America chief, effective Aug. 1 July 20, 2026 8:20 AM - StreetInsider Roche Appoints Dan Malarek as President and CEO of Roche Diagnostics North America July 20, 2026 8:20 AM - PR NewsWire FDA grants priority review to Genentech's Gazyva for kidney disease July 15, 2026 1:01 AM - StreetInsider FDA Grants Priority Review to Genentech’s Gazyva for Adults With Primary Membranous Nephropathy July 15, 2026 1:01 AM - BizWire Genentech and Roche Present New Data in Alzheimer’s Disease From Across Its Integrated Pharmaceutical and Diagnostics Portfolio at AAIC July 7, 2026 1:01 AM - BizWire HSBC Downgrades Roche Holding (ROG:SW) (RHHBY) to Hold July 6, 2026 1:32 AM - StreetInsider Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer July 2, 2026 1:10 AM - BizWire FDA grants priority review to Genentech's Enspryng for thyroid eye disease June 30, 2026 1:09 AM - StreetInsider FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED) June 30, 2026 1:09 AM - BizWire FDA accepts Genentech's application for Lunsumio and Polivy combo June 18, 2026 1:00 AM - StreetInsider FDA Accepts Supplemental Biologics License Application for Genentech’s Lunsumio and Polivy Combination for People With Relapsed or Refractory Large B-Cell Lymphoma June 18, 2026 1:00 AM - BizWire FDA grants priority review for Genentech's Tecentriq in stage III colon cancer June 11, 2026 1:05 AM - StreetInsider FDA Grants Priority Review for Genentech’s Tecentriq for a Certain Type of Stage III Colon Cancer June 11, 2026 1:05 AM - BizWire Roche's VENTANA MMR RxDx Panel companion diagnostic receives IVDR approval across multiple cancer types and therapies June 11, 2026 1:00 AM - PR NewsWire Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology June 8, 2026 1:00 AM - Globe NewsWire Full Article List